TY - JOUR
T1 - Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients
AU - Keularts, I. M. L. W.
AU - Beguin, S.
AU - de Zwaan, C.
AU - Hemker, H. C.
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.
AB - Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.
U2 - 10.1055/s-0037-1615213
DO - 10.1055/s-0037-1615213
M3 - Article
SN - 0340-6245
VL - 80
SP - 370
EP - 371
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 3
ER -